Recent Research Analysts’ Ratings Changes for Liquidia (LQDA)

Liquidia (NASDAQ: LQDA) has recently received a number of price target changes and ratings updates:

• 3/7/2026 – Liquidia was upgraded by Wall Street Zen from “hold” to “buy”.
• 3/6/2026 – Liquidia had its price target raised by Wells Fargo & Company from $31.00 to $44.00. They now have an “overweight” rating on the stock.
• 3/6/2026 – Liquidia had its price target raised by HC Wainwright from $50.00 to $55.00. They now have a “buy” rating on the stock.
• 3/5/2026 – Liquidia had its “strong-buy” rating reaffirmed by Raymond James Financial, Inc..
• 3/5/2026 – Liquidia was upgraded by Lifesci Capital to “strong-buy”.
• 3/5/2026 – Liquidia had its price target raised by BTIG Research from $49.00 to $50.00. They now have a “buy” rating on the stock.
• 3/5/2026 – Liquidia had its price target raised by Needham & Company LLC from $52.00 to $54.00. They now have a “buy” rating on the stock.
• 2/27/2026 – Liquidia was downgraded by Zacks Research from “strong-buy” to “hold”.
• 2/25/2026 – Liquidia had its “buy” rating reaffirmed by Needham & Company LLC. They now have a $52.00 price target on the stock.
• 1/22/2026 – Liquidia had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 1/18/2026 – Liquidia was downgraded by Wall Street Zen from “buy” to “hold”.
• 1/13/2026 – Liquidia had its price target raised by Jefferies Financial Group Inc. from $45.00 to $55.00. They now have a “buy” rating on the stock.
• 1/13/2026 – Liquidia had its price target raised by Jefferies Financial Group Inc. from $45.00 to $55.00. They now have a “buy” rating on the stock.
• 1/13/2026 – Liquidia was upgraded by Zacks Research from “hold” to “strong-buy”.
• 1/10/2026 – Liquidia was upgraded by Wall Street Zen from “hold” to “buy”.
• 1/9/2026 – Liquidia had its “buy” rating reaffirmed by BTIG Research. They now have a $49.00 price target on the stock.

Insider Transactions at Liquidia

In other news, General Counsel Russell Schundler sold 27,289 shares of the company’s stock in a transaction dated Monday, January 12th. The stock was sold at an average price of $37.43, for a total value of $1,021,427.27. Following the transaction, the general counsel owned 579,394 shares in the company, valued at $21,686,717.42. This represents a 4.50% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Scott Moomaw sold 20,533 shares of the stock in a transaction that occurred on Monday, January 12th. The stock was sold at an average price of $37.43, for a total transaction of $768,550.19. Following the completion of the sale, the insider directly owned 154,514 shares of the company’s stock, valued at $5,783,459.02. This trade represents a 11.73% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 212,534 shares of company stock worth $7,964,719. 30.10% of the stock is currently owned by insiders.

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).